Start & finish are two different things. The question is production & distribution of vaccines & that means the reach of the vaccines to get to the 70% of the population needed to get herd immunity. The math right now tells us that we're looking at a solution that takes time.
https://twitter.com/CNBCJulianna/status/1330594561828286464
Comparison of the 2 vaccines (Pfizer just updated that it's 95% too) so both good results but details tell you that we need to over come the following:
*Production
*Distribution.
Let's discuss those issues!
*Production
*Distribution.
Let's discuss those issues!
Pfizer: 50m does by 2nd 2020 & 1.3bn in 2021.
For Moderna: 20m by end 2020 & 500m-1bn.
Meaning that we're likely to get 70m by end 2020 & have to wait for 2021 to get somewhere between 1.8bn to 1.3bn.
These vaccines require 2 dosages. Priority will be healthcare + elderly.
For Moderna: 20m by end 2020 & 500m-1bn.
Meaning that we're likely to get 70m by end 2020 & have to wait for 2021 to get somewhere between 1.8bn to 1.3bn.
These vaccines require 2 dosages. Priority will be healthcare + elderly.
Beyond production issues, which means that the availability of this will be geared towards US & developed markets vs global, there is a distribution issue.
Moderna is better as it can be stored at -20C vs Pfizer at -80C. Typical freezer is -20C so question about storage of this.
Moderna is better as it can be stored at -20C vs Pfizer at -80C. Typical freezer is -20C so question about storage of this.
Why? Because Pfizer shines in production (more capability) but worse than Moderna is distribution due to requirement of better storage facilities.
Demand for dry ice has risen due to expectations of needing for storage. In other words, good but question mark for emerging markets
Demand for dry ice has risen due to expectations of needing for storage. In other words, good but question mark for emerging markets
• • •
Missing some Tweet in this thread? You can try to
force a refresh
